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Abstract
Introduction In intensive care unit patients we assessed, using bispectral index (BIS) monitoring,
whether the addition of magnesium sulphate infusion could decrease the sufentanil infusion required to
maintain sedation.
Patients and methods A total of 30 adult patients who were expected to require machanical
ventilation for 6 hours in the intensive care unit were randomly assigned to receive either sufentanil
infusion or sufentanil plus magnesium infusion. We monitored BIS levels continously. BIS levels in the
range 61–88 are required to maintain a state of sedation, and in both groups BIS levels were kept
within this range by increasing or decreasing the sufentanil infusion. Hourly consumption of sufentanil
was monitored. Cardiovascular, respiratory and biochemical data were recorded.
Results There was no significant difference between the groups with respect to cardiovascular,
respiratory and biochemical parameters. Magnesium infusion, when added to sufentanil infusion,
decreased the consumption of sufentanil at all times accept during the first hour (P<0.001). There
was no significant difference in BIS values between the groups (P>0.05).
Conclusion This is the first clinical study to demonstrate that magnesium sulphate infusion decreases
sufentanil requirements. Because of the limited number of patients included and the short period of
observation, our findings must be confirmed by larger clinical trials of magnesium infusion titrated to
achieve prespecified levels of sedation. Furthermore, randomized clinical studies are needed to
determine the effects of magnesium infusion on opioids.
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Introduction
Inadequate sedation may adversely affect morbidity and even
mortality in the intensive care unit (ICU), and the search for
the ideal sedative agent therefore continues [1,2]. Sedation is
an important part of therapy for critically ill patients in the ICU.
It reduces anxiety and stress, facilitates sleep, prevents
injuries and accidental removal of catheters, reduces resis-
tance to mechanical ventilation, and decreases oxygen con-
sumption in severe head injury [2]. Under-sedation may result
in hypertension, tachycardia, discomfort and resistance toR124
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mechanical ventilation. Hypotension, bradycardia, coma, res-
piratory depression, immunosuppression, paralytic ileus and
renal failure are among the risks associated with over-seda-
tion [2,3]. Use of combinations of hypnotics and opiates for
sedation has become common.
Bispectral electroencephalographic analysis was recently
developed, and the effects of many anaesthetic agents on
levels of sedation have been studied using bispectral index
(BIS) monitoring. These reports suggest that BIS levels corre-
late well with depth of sedation [4,5]. Only a few investigators
have studied the validity of BIS monitoring in ICU patients, but
a correlation between BIS levels and sedation scales in ICU
patients has been reported for various agents [6,7].
Sufentanil allows rapid emergence from sedation and less
respiratory depression than occurs with other sedative
agents, and it maintains haemodynamic stability [8]. It is an
effective analgesic and its rapid onset of action allows simple
titration, according to individual patient tolerance, to the the
desired clinical end-point. Furthermore, its short duration of
action means that the desired analgesic effect will continue
for as long as the infusion is continued, and any undesirable
side effects will be short-lived following discontinuation [9]. In
addition, mechanically assisted spontaneous ventilation
modes can safely be used under continuous sedation with
sufentanil [10].
Magnesium sulphate is involved in several processes, includ-
ing hormone receptor binding, gating of calcium channels,
transmembrane ion flux and regulation of adenylate cyclase,
muscle contraction, neuronal activity, control of vasomotor
tone, cardiac excitability and neurotransmitter release. In
many of its actions it has been likened to a physiological
calcium channel blocker [11].
In the present study, conducted in ICU patients, we assessed
(using BIS monitoring) whether the addition of magnesium
sulphate infusion could decrease the sufentanil infusion
required to maintain sedation.
Patients and method
Patient population and study design
The study was approved by the regional committee on
medical research ethics. Written informed consent was
obtained directly from the patients whenever possible, or
from their next of kin.
A total of 30 adult patients (trauma, general surgical and
medical) requiring mechanical ventilatory support were
enrolled in this prospective analysis. The initial severity of
illness was determined using Acute Physiology and Chronic
Health Evaluation (APACHE) II [12] scores. Patients with
overt disease affecting the brain (e.g. head trauma, intracra-
nial haemorrhage, meningitis or stroke) and those receiving
neuromuscular blocking agents were excluded.
Patients were ventilated mechanically with oxygen enriched
air to achieve acceptable blood gas levels. If required,
patients underwent surgical procedures before the start of
the study. No invasive surgery was performed during the
24 hour study period. Ventilator settings, level of positive end-
expiratory pressure and fractional inspired oxygen were kept
constant during sufentanil and magnesium infusion.
Antibiotic treatment was adjusted in accordance with results
of bacteriological culture, such as culture of blood or of
samples taken from different sites of the body. No inotropic
agent was administered during the study.
Protocol
The study was prospective, randomized, double blind, and
placebo-controlled. Randomization was conducted according
to a computer directed, permutated block design. In accor-
dance with the double blind protocol, drug solutions and infu-
sions were administered to patients by a nurse who had no
knowledge of the study protocol. The BIS was monitored
using a BIS Monitor Model A-2000 (Aspect Medical Systems
Inc., Newton, MA, USA). After placement of the BIS electrode
(Aspect Medical Systems Inc., Natick, MA, USA) above the
bridge of the nose, over the temple area, and between the
eye and hairline, the monitor undergoes automic impedence
testing to ensure acceptable signal reception. When an inad-
equate signal is sensed the display’s colour pattern changes,
allowing easy differentiation between true and spurious
values. Electrodes were repositioned or replaced if imped-
ances increased to the extent that electroencephalographic
evaluation was impaired. The degree of sedation was mea-
sured continously using BIS monitoring. Patients were main-
tained at BIS levels in the range 61–88, which are associated
with a sedated state.
At the start of the study all patients received 1µg/kg sufen-
tanil by intravenous bolus. Immediately after, groups 1 and 2
received an intravenous sufentanil infusion for 6 hours, but
group 2 also received an intravenous infusion of magnesium
sulphate (2g/hour) for 6 hours via a dedicated central venous
catheter. Average BIS values were kept in the range 61–88
by decreasing or increasing sufentanil infusion in both
groups, and hourly consumption of sufentanil was monitored.
Evidence of hypocalcaemia was sought using clinical signs
(Chvostek’s and Trousseau’s) and measurement of total
serum calcium concentrations. Effects of elevated magne-
sium include flushing, loss of tendon reflexes, respiratory
arrest, and prolongation of the PR interval and the QRS
complex; these were also evaluated.
The sedative infusion was discontinued when cardiovascular
and respiratory adverse events were identified, defined as a
change in arterial pressure of more than 40% from baseline,
bradycardia to less than 50 beats/min, or tachyarrhythmia. No
other sedative or analgesic agents were given, and no patient
received spinal or epidural analgesia in the ICU.R125
Measurements
All patients underwent placement of arterial catheters and
central venous catheters via the subclavian vein. Arterial
blood samples were drawn for measurements of pH, oxygen
and carbon dioxide tensions, and arterial oxygen saturation
(Medica Easy BloodGas; Massachusetts, USA). Central
venous pressure, mean arterial pressure, heart rate and
nasopharyngeal temperature were continuously monitored
(SpaceLabs Inc., Redmond, USA). Sodium, potassium,
calcium (Ilyre, Ion Selective Electro Analyzer; LISpA, Milan,
Italy), magnesium levels (Merek Mega, Darmstadt, Germany),
and bilirubin, alanine aminotransferase and creatinine (Vitalab
Flexor, Dieren, The Netherlands) were determined at baseline
(15 min before start of the study), immediately after sedative
infusion and 24 hours after sedative infusion.
Statistics
Demographic data; haemodynamic, biochemical and arterial
blood gas changes; sufentanil dose; and changes in BIS
were analyzed using independent samples t tests. Data were
expressed as means±standard deviation. P<0.05 was con-
sidered statistically significant.
Results
Patient characteristics
Clinical and demographic characteristics of the patients are
summarized in Table 1. Of the 30 patients included in the
study, 15 received sufentanil (group 1) and 15 received
sufentanil plus magnesium (group 2). Eight patients died
while they were hospitalized in the ICU for reasons related to
infection (four in group 1 and four in group 2). Baseline
APACHE II scores (12.3±4.3 and 13.4±4.6 in groups 1 and
2, respectively) and central venous pressure (5.9±2.4mmHg
and 5.6±2.7mmHg) were similar between groups (P>0.05).
The sufentanil infusion and the sufentanil plus magnesium
infusion were well tolerated by all patients, and no adverse
effects were noted.
Haemodynamic parameters and oxygen transport
variables
There was no significant difference between the groups with
respect to pH, oxygen or carbon dioxide tension, ratio of arte-
rial oxygen tension to fractional inspired oxygen, and arterial
oxygen saturation (P>0.05). No significant change in heart
rate or mean arterial pressure was found in either group
(Table 2). There was no significant difference between
groups in biochemical parameters or temperature (P>0.05).
Sedation
Magnesium sulphate infusion, when added to sufentanil infu-
sion, decreased the consumption of sufentanil at all times
except during the first hour (P<0.001; Fig.1). There was no
significant difference between the groups in terms of BIS
values (P>0.05; Fig.2).
Outcome
The overall hospital mortality rate was similar in both groups
(26.6%). All of those who died did so while being mechani-
cally ventilated. Mean survival time was 7±3 days in the
group receiving sufentanil plus magnesium sulphate and
7±4 days in the group receiving sufentanil alone. The dura-
tion of mechanical ventilation and the number of ventilator
free days (calculated as the number of days a patient was
alive and without mechanical ventilation at 28 days) were
similar between the groups. In the sufentanil and sufentanil
plus magnesium groups, ventilation duration was 6±2 and
7±3 days and number of ventilator free days was 9±3 and
8±4 days, respectively (P>0.05).
Side effects
No side effects were noted during or after administration of
sufentanil infusion and sufentanil plus magnesium infusion.
Discussion
Sedatives are common adjuncts in the treatment of anxiety
and agitation. The causes of anxiety in critically ill patients are
multifactorial and probably secondary to the continuous noise
(making it impossible to communicate), continuous ambient
lighting and excessive stimulation (inadequate analgesia, fre-
quent vital sign monitoring, repositioning, lack of mobility and
room temperature) that are characteristic of the ICU setting.
Efforts to reduce anxiety, including frequent reorientation,
maintenance of patient comfort, provision of adequate anal-
gesia and optimization of the environment, may be supple-
mented with sedatives [1,2].
The BIS of the electroencephalogram is an empirical, statisti-
cally derived variable that provides information about the
interaction of brain cortical and subcortical regions. Sigl and
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Table 1
Clinical characteristics of the patients included
Group 1 Group 2
Characteristic (n=15) (n=15)
Age (years) 48.2±6.4 51.1±5.3
Weight (kg) 62.3±8.55 64.5±7.8
APACHE II score 12.3±4.3 13.4±4.6
Death (n)4 4
Aetiology (n)
Medical 4 5
General surgical 6 4
Trauma 5 6
There were no significant differences between groups. Group 1
received sufentanil infusion alone, whereas group 2 received sufentanil
plus magnesium sulphate. Unless otherwise stated, values are
expressed as means±standard deviation. APACHE, Acute Physiology
and Chronic Health Evaluation.R126
Chamoun [13] reported technical details and rationale for the
use of BIS. First, BIS provides information regarding interac-
tion between cortical and subcortical areas, which changes
with increasing amounts of hypnotic drugs. Second, the BIS
is an empirical, statistically derived measurement that was
developed by analyzing a large database of electro-
encephalograms from individuals who had received hypnotic
agents. Third, the BIS measures a state of the brain and not
the concentration of a particuler drug. Fourth, interpretation of
the BIS is based on the assumption that sedation is intended
to produce a state of sleep that includes a lack of awareness
and a lack of recall, whereas analgesia is intended to produce
a state of reduced pain perception manifested by decreased
autonomic responses to noxious stimuli. Finally, in general a
BIS score of 100 reflects the awake state, 80 reflects some
sedation, 60 reflects a moderate level of hypnosis, and 40
reflects a deep hypnotic state [14]. In the present study BIS
values were maintained in the range 61–88.
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Table 2
Hemodynamic parameters, and calcium and magnesium levels
Period after sedative infusion
Parameter/level Baseline Immediately after 2 hours 4 hours 6 hours 24 hours 
Heart rate (beats/min)
Group 1 90±12 89±11 88±12 90±13 92±11 91±13
Group 2 88±11 91±9 89±11 88±12 90±12 88±12
Mean arterial pressure (mmHg)
Group 1 74.1±9.2 73.5±14 76.3±9.5 77±12.5 75±12.5 75±8.5
Group 2 75.2±8.8 74±10.7 76.4±12.0 74±14.8 74±14.8 73±9.8
Calcium (8.9–10.3 mg/dl)
Group 1 9.2±1.1 9.1±1.2 9.0±1.3
Group 2 9.1±1.3 8.9±1.1 8.9±1.2
Magnesium (1.8–3.5 mg/dl)
Group 1 3.06±0.83 3.07±0.79 3.08±0.68
Group 2 2.97±0.95 4.0±1.31 3.1±0.73
There were no statistically significant differences between groups (P > 0.05). Group 1 (n = 15) received sufentanil infusion alone, whereas group 2
(n = 15) received sufentanil plus magnesium sulphate. Values are expressed as means±standard deviation.
Figure 1
Hourly consumption of sufentanil. Group 1 (n=15) received
sufentanil infusion alone, whereas group 2 (n=15) received
sufentanil plus magnesium sulphate. Data are expressed as
means±standard deviation. *P<0.001, group 1 versus group 2.
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Figure 2
Hourly bispectral index (BIS) values. No statistically significant
differences were found between the groups (P>0.05). Group 1
(n=15) received sufentanil infusion alone, whereas group 2 (n=15)
received sufentanil plus magnesium sulphate. Data are expressed as
means±standard deviation.
Hours
B
I
S
 
v
a
l
u
e
s
20
40
60
80
100
120
140
Baseline 1 2 3 4 5 6
Group 1
Group 2R127
BIS is a processed electroencephalographic measurement
that correlates with the sedative properties of single anaes-
thetic agents. Use of combinations of hypnotics and opiates
to achieve sedation has become common. BIS is useful in the
ICU for monitoring sedation (and preventing over-sedation)
and for shortening the duration of ICU stay, and a conse-
quent decrease in hospital costs associated with its use may
be anticipated [15]. However, several questions have been
raised regarding the use of BIS in the ICU concerning the
widespread use of opioids (which reduces the validity of BIS)
[15,16], interpretation difficulties in neurological diseases [17]
and controversial studies that demonstrated decreased corre-
lation between clinical sedation scores and BIS [17–19]. For
example, a study conducted in a paediatric ICU [20] demon-
strated that opioids do provide some degree of sedation.
Kroll and List [21] found analgesia and sedation with sufen-
tanil to be satisfactory in critically ill patients. At a dosage
range of 0.75–1.0µg/kg per hour, this drug can safely be
given to patients undergoing controlled mechanical ventila-
tion. Wappler and coworkers [22] found that continuous infu-
sion of sufentanil (1µg/kg per hour was given initially) for
analgesia and sedation is suitable for intensive care patients
with a short stay in the ICU. Prause and colleagues [10]
found that critically ill patients under continuous sedation with
sufentanil (median 0.44µg/kg per hour) exhibit a statistically
significant rise in arterial carbon dioxide tension, but this res-
piratory depression is only slight and has no clinical signifi-
cance. Mechanically assisted spontaneous ventilation modes
can safely be used under continuous sedation with sufentanil.
In the present study all patients initially received 1µg/kg
sufentanil by intravenous bolus.
There is a suggested role for magnesium in almost every phys-
iological system. Key underlying mechanisms of action are
those of calcium antogonism via calcium channels, regulation
of energy transfer, and membrane sealing or stabilization
[23,24]. This has led to several studies on the central and
peripheral nervous systems, and the cardiovascular, respira-
tory, endocrine and reproductive systems. Magnesium’s action
as an anticonvulsant is secondary to antagonism at N-methyl-
D-aspartate receptors [25]. Stimulation of this subgroup of
glutamate receptors is known to lead to excitatory postsynap-
tic potentials, causing seizures. Magnesium has successfully
been used as an anticonvulsant in eclampsia [26].
In addition, magnesium is known to have a marked antiadren-
ergic effect. This is mediated by a variety of mechanisms, of
which the most important is probably calcium channel block-
ade. Calcium plays a fundamental role in stimulus–response
coupling of catecholamine release from the adrenal medulla
and adrenergic nerve terminals, and its role in adrenal cate-
cholamine release is well described [11]. In tetanus, magne-
sium has been used to treat both muscle spasm and
autonomic dysfunction, which leads to large increases in cat-
echolamine release [27].
Calcium channel blockers have antinociceptive effects in
animals and potentiate the analgesic effects of morphine in
patients with chronic pain [28,29]. As mentioned above, mag-
nesium is also an antagonist of N-methyl-D-aspartate receptor
ion channels, and this may explain part of its analgesic activity
[30]. The analgesic effect of magnesium has been demon-
trated both in human and in animal studies. Its effect on
decreasing perioperative analgesic [31] and anaesthetic [32]
requirements was demonstrated in various studies. In the
present study, under highlights of magnesium’s effects, when
used for sedation/analgesia in ICU, we aimed to investigate
the influence on sufentanil dose. Attygalle and Rodrigo [27]
administered 2–3g/hour magnesium in tetanus. In the present
study we used a similiar dose of 2g/hour magnesium.
Magnesium is utilized in the control of spasms in eclampsia and
the safety of the therapeutic range (2–4mmol/l) is well estab-
lished, because areflexia only occurs at levels above 4mmol/l
and muscle paralysis above 6mmol/l [27]. Magnesium does
not cause sedation at serum concentrations below 8mmol/l as
long as ventilation is adequate (because it does not easily
cross the blood–brain barrier) [27]. Attygalle and Rodrigo [27]
administered 2–3g/hour magnesium in tetanus. Those investi-
gators found that magnesium sulphate can be used as the sole
agent for the control of spasms in tetanus without the need for
sedation and artificial ventilation. In our study serum magne-
sium concentrations did not increase to above 5mmol/l but
these concentrations increased the effectiveness of sufentanil
when the agents were administered together.
However, the patients studied here were not postoperative
patients and were not extubated at the end of the study; we
were therefore unable to evaluate the effect of infusion of
sufentanil plus magnesium on extubation criteria. We aimed
to determine the effect of sufentanil plus magnesium infusion
over a short period of time. Further studies in postoperative
patients are needed to determine effects of sufentanil plus
magnesium infusion on extubation criteria.
This is the first clinical study to demonstrate that magnesium
infusion decreases sufentanil requirements. Because of the
limited number of patients included and the short period of
observation, our findings must be confirmed by larger clinical
trials of magnesium infusion titrated to achieve prespecified
levels of sedation. Furthermore, randomized clinical studies
are needed to determine the effects of magnesium infusion
on opioids.
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Key messages
• We assessed whether the addition of magnesium 
infusion in ICU patients decreased the sufentanil
requirements using bispectral index
• This clinical study demonstrated that magnesium 
infusion decreased sufentanil requirementsR128
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